Search Results for "Imcmage1"
Original Source: Revolutionary new cancer targeting technology described in Nature Medicine
(Oxford, UK, 6th May 2012) A revolutionary cancer-targeting technology developed by researchers at Immunocore Limited has been described for the first time in the prestigious medical journal, Nature Medicine. The new reagents known as ImmTACs (Immune Mobilising mTCR against Cancer) mobilise T cells to kill cancer cells and overcome immune tolerance to cancer. The most advanced of Immunocore’s ImmTACs, a drug called IMCgp100, is already in clinical trials in the UK and US for the treatm...
Matching Channels
None
Matching News
Revolutionary new cancer targeting technology described in Nature Medicine
(Oxford, UK, 6th May 2012) A revolutionary cancer-targeting technology developed by researchers at Immunocore Limited has been described for the first time in the prestigious medical journal,...
Matching PubMed Articles
None
